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C O N T I N U E D
Is nedocromil effective in
preventing asthmatic attacks
in patients with asthma? 
■ EVIDENCE-BASED ANSWER
Nedocromil (Tilade) is effective for the treatment
of mild persistent asthma. It has not been shown
to be effective in more severe forms of asthma for
both children and adults. Although no studies
looked specifically at exacerbation rates, multiple
clinical and biologic outcomes (symptom scores,
quality of life measures, bronchodilator use,
forced expiratory flow in 1 second [FEV1], and
peak expiratory flow rate [PEFR]) improved with
nedocromil use compared with placebo. 
The most effective dose for preventing exacer-
bations appears to be 4 mg (2 puffs) 4 times a day
(SOR: A, multiple randomized controlled trials
[RCTs] and meta-analyses). More severe forms of
asthma respond better to inhaled steroids than to
nedocromil (SOR: A, multiple RCTs). Nedocromil
may allow some patients with severe asthma to
use lower doses of inhaled steroids (SOR: C, con-
flicting RCTs). Nedocromil is also effective for the
treatment of exercise-induced asthma (SOR: A,
multiple RCTs and meta-analyses). 
In general, about 50% to 70% of patients
respond to nedocromil (SOR: A, multiple RCTs and
meta-analyses). Unfortunately, which patients
respond is not predictable from clinical parame-
ters.1 Nedocromil is worth trying in mild persistent
asthma, particularly for children where the parents
are worried about the growth issues associated
with inhaled steroids. Side effects (sore throat, nau-
sea, and headache) are mild and infrequent.
Maximal efficacy is usually seen after 6 to 8 weeks.
■ EVIDENCE SUMMARY
A systematic review encompassing 127 trial cen-
ters and 4723 patients concluded that inhaled
nedocromil was effective for a variety of patients
with asthma. Significant improvements were
noted in FEV1, PEFR, use of bronchodilators,
symptom scores, and quality of life scores. The
reviewers found nedocromil to be most effective
for patients with moderate disease already taking
bronchodilators,2 corresponding to the “mild per-
sistent asthma” category (Table). 
A contemporaneous European RCT, not includ-
ed in the review, compared 4 mg of inhaled
nedocromil 4 times daily with inhaled placebo
among 209 asthmatic children for 12 weeks.3
After 8 weeks, they found a statistically significant
reduction in total daily asthma symptom scores
(50% nedocromil vs 9% placebo; P<.01). The pro-
portion of parents and children rating treatment as
moderately or very effective was 78% in the treat-
ment group and 59% in the placebo group (number
needed to treat [NNT]=5.2; P<.01); clinicians’ rat-
ings were 73% for nedocromil and 50% for placebo
(NNT=4.3; P<.01). The frequency of side effects—
including nausea, headache, and sleepiness—did
not reach statistical significance; however, the
nedocromil group reported up to a 20% incidence
of sore throat. Most of the studies reported no
dropouts due to side effects. 
When patients are already using inhaled
steroids, the evidence is less clear whether
nedocromil confers additional benefits, such as
fewer exacerbations or lower inhaled steroid
doses. Two small studies of patients either
already on inhaled steroids4 or considered to be
steroid-resistant5 found nonsignificant trends
towards reductions in bronchodilator use,
increased PEFR, increased FEV1, and improved
quality of life. Although both studies were under-
powered, the study on steroid-resistant asthma
did find a statistically significant 20% improve-
ment in PEFR and decreased bronchodilator use
for 50% of patients at 8 and 12 weeks. 
The inherent waxing and waning nature of
asthma makes demonstrating benefits difficult.
Furthermore, nedocromil tends to have an all-or-
nothing effect rather than a dose-response gradi-
ent. Unfortunately, none of these trials found use-
ful predictors to help clinicians determine which
patients respond.1,5
In a Cochrane Review, 20 RCTs involving 280
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participants showed that 4 mg (2 puffs) of
nedocromil inhaled 15 to 60 minutes prior to exer-
cise significantly reduced the severity and duration
of exercise-induced asthma for both adults and chil-
dren. The maximum percentage fall in FEV1
improved significantly compared with placebo, with
a weighted mean difference of 15.5% (95% confi-
dence interval, 13.2–18.1). In addition, the time to
complete recovery was shortened from 30 minutes
with placebo to 10 minutes with nedocromil.6
■ RECOMMENDATIONS FROM OTHERS
The Global Initiative for Asthma and the National
Heart, Lung and Blood Institute Expert Panel
Report list nedocromil as an option for the treat-
ment of exercise-induced asthma and mild per-
sistent asthma for adults and children. However,
it is listed as a second choice to the use of inhaled
steroids in the case of mild persistent asthma. It
is not recommended for moderate or severe per-
sistent asthma, or for mild intermittent asthma.7
Tim Dudley, MD, Sandi Parker, MILS, University of
Colorado Health Sciences Center, Denver
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■ CLINICAL COMMENTARY
Nedocromil and cromolyn sodium are 
safe but many patients do not respond
Inhaled nedocromil and cromolyn sodium
have long been recognized as agents with an
excellent safety profile. Unfortunately, as
pointed about above, many patients do not
respond to these agents. In addition, 4-times-
daily dosing makes compliance difficult.
Clinicians and parents must weigh the theo-
retical risk of inhaled corticosteroid-induced
growth retardation with this potential differ-
ential in effectiveness. 
Ron Baldwin, MD, University of Wyoming Family
Practice Residency at Casper
Appli
Classification of asthma
Classification Symptom frequency Spirometry findings
Severe persistent Continual symptoms PEFR <60%
Variability >30%
Moderate persistent Daily symptoms, more PEFR >60% but <80%
than 1 night per week Variability >30%
Mild persistent More than twice per week but less PEFR >80%
than daily; more than 2 nights per month Variability 20%–30%
Mild intermittent Less than once per week; less than PEFR >80%
or equal to 2 nights per month Variability <20%
Source: Global Initiative for Asthma, National Heart, Lung and Blood Institute 2003.7
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